FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a drug for multiple sclerosis which is presented in the form of a pharmaceutical composition and contains an activated potentiating form of human gamma-interferon (IFN-γ) antibodies and an activated potentiating form of brain-specific protein S-100 antibodies as an additive intensifying component. Using the drug in a method for treating multiple sclerosis involves in introduction of the activated potentiating form of human gamma-interferon (IFN-γ) in combination with the intensifying component in the form of the activated potentiating form of very-low-dose affinity purified brain-specific protein S-100 antibodies.
EFFECT: use of the inventions allows higher clinical effectiveness in multiple sclerosis.
9 cl, 1 ex
